Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacinamide in Acute Kidney Injury
NCT02701127Phase 1Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of nicotinamide in acute kidney injury (AKI), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Changes from baseline in serum metabolite profile of niacinamide at day 4. Started Mar 2016; status: completed.
02
Drugs
nicotinamide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT02701127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02701127.